Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
DETERMINANTS OF REDUCED 6-MINUTES WALKING DISTANCE AND ITS PROGNOSTIC VALUE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Anno:
2025
Background: The six-minute walk test (6MWT) is a reliable measure of exercise capacity in patients suffering from cardiovascular diseases. While the prognostic significance of a reduced six-minute walk distance (6MWD) is well-established, there remains a paucity of comprehensive data on the factors that predict performance on this test. Purpose: To evaluate…
Leggi di più
PCSK9-TARGETING DRUGS AND GENDER: EFFICACY, SAFETY AND ADHERENCEPCSK9-TARGETING DRUGS AND GENDER: EFFICACY, SAFETY AND ADHERENCEPCSK9-TARGETING DRUGS AND GENDER: EFFICACY, SAFETY AND ADHERENCE
Anno:
2025
Background: Research has indicated a gender disparity in dyslipidemia management, with women being significantly more likely to fail to meet LDL-C targets and less likely to receive high-intensity lipid-lowering medications in response to elevated LDL-C levels. The aim of this analysis was to highlight potential gender differences in response…
Leggi di più
THE COEXISTENCE OF A SHORTER 6MWD AND HYPOVITAMINOSIS D DOUBLES ADVERSE OUTCOME RISK IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Anno:
2025
Background: The six-minute walk test (6MWT) reliably assesses exercise capacity of patients. Vitamin D influences muscle strength and function promoting protein synthesis and regulating calcium and phosphate levels.  Purpose: To evaluate the relationship between hypovitaminosis D levels and 6MWT results, and their prognostic significance in patients with acute myocardial infarction (AMI). …
Leggi di più
CARDIOVASCULAR OUTCOMES IN DIABETIC PATIENTS TREATED WITH SGLT2i AND GLP1-RA: SYSTEMATIC REVIEW AND META-ANALYSIS
Anno:
2025
Background. SGLT2-i (sodium-glucose cotrasporter-2 inhibitor) and GLP1-RA (glucagon-like peptide receptor agonist) are two new classes of glucose-lowering drugs for the treatment of diabetes mellitus. Several important randomized clinical trials demonstrated a reduction in the risk of cardiovascular events in patients with type 2 diabetes mellitus treated with SGLT2-i and GLP1-RA….
Leggi di più
Association between regular sport activity and resting heart rate values in a cross-sectional adolescent study
Anno:
2025
A collaborative project between the ABC Study on Heart Disease Foundation and Liceo Guglielmo Marconi. Background: Resting heart rate (RHR) is a crucial physiological parameter that reflects autonomic regulation, cardiovascular function, and overall health. In adolescents, regular physical activity, particularly sports, has been associated with improved cardiovascular efficiency, resulting…
Leggi di più
EVALUATION OF DIAGNOSTIC ACCURACY OF EXTREME CARDIOVASCULAR RISK DEFINITIONS IN ACUTE CORONARY SYNDROME PATIENTS
Anno:
2025
Background: In 2022 the European Society of Cardiology published a consensus paper with six definitions of extreme cardiovascular (CV) risk. In secondary the gold standard is definition 2: two cardiovascular events within two years. Commonly used are also acute coronary syndrome (ACS) combined with peripheral or polyvascular disease (definition…
Leggi di più
FEMALE HEAVY SMOKERS WITH ATYPICAL CHEST PAIN AND NEGATIVE FUNCTIONAL TESTS: ARE WE UNDERESTIMATING THE RISK?
Anno:
2025
BACKGROUND. Women are generally considered at low risk for cardiovascular disease. This led to gender bias and udertreatment of female patients. Women were inadequately represented in clinical trials for a long time, so that scores used in clinical practice  may not be effective in assessing their risk. Moreover, in…
Leggi di più
BENEFITS OF BEMPEDOIC ACID TREATMENT IN CARDIOVASCULAR RISK PATIENTS: DATA FROM A SINGLE-CENTRE EXPERIENCE
Anno:
2025
Background: cardiovascular diseases (CVDs) remain the leading global cause of morbidity and mortality, driven by risk factors such as dyslipidemia, which needs effective lipid-lowering strategies. Bempedoic acid, a novel non-statin lipid-lowering agent, acts by inhibiting ATP citrate lyase, reducing low-density lipoprotein cholesterol (LDL-C) synthesis. Many clinical trials have demonstrated its…
Leggi di più
Hormonal therapy-induced severe dyslipidemia
Anno:
2025
Background: Apulatamide, a nonsteroidal androgen receptor inhibitor, and degarelix, a gonadotrophin releasing hormone antagonist, are used as hormonal therapies for advanced prostate cancer (aPC) treatment. However, they may increase the risk of cardio-metabolic diseases which are the main cause of non-cancer-related death in patients with PC. We report a…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram